Healthcare - Biotechnology - NASDAQ - US
$ 1.08
-4.42 %
$ 1.16 M
Market Cap
0.0
P/E
INCOME STATEMENT
0
REVENUE
-14.4 M
OPERATING INCOME
-98.3 M
NET INCOME
EFFICIENCY
Earnings Waterfall
ZyVersa Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 10.4 K |
| Gross Profit | -10.4 K |
| Operating Expenses | 14.4 M |
| Operating Income | -14.4 M |
| Other Expenses | 83.9 M |
| Net Income | -98.3 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|
| REVENUE | ||||
| Revenue | 0 | 0 | 0 | 0 |
| GROSS PROFIT | ||||
| Cost Of Revenue | 10.4 K | 10.4 K | 10.4 K | 10.4 K |
| Gross Profit | 10.4 K | 10.4 K | 10.4 K | 10.4 K |
| OPERATING INCOME | ||||
| Operating Expenses | 14.4 | 13.0 | 7.7 | 11.8 |
| Selling, General and Administrative Expenses | 11.2 | 7.6 | 5.6 | 5.4 |
| Research and Development Expenses | 3.2 | 5.4 | 2.1 | 6.5 |
| Operating Income | (14.4) | (13.0) | (7.7) | (11.8) |
| PRE-TAX INCOME | ||||
| Interest Income Expense | (0.5) | 0.4 | 0.8 | 0.5 |
| Total Other Income | (93.3) | (2.4) | (0.4) | (0.9) |
| Pre-Tax Income | (107.8) | (14.0) | (8.1) | (12.7) |
| NET INCOME | ||||
| Tax Provision | (9.5) | 745.0 | 0.8 | 0.5 |
| Net Income | (98.3) | (759.1) | (8.9) | (13.2) |
| EPS | 1.09 K | 2.93 K | 19.1 | 28.4 |